DPY30: Potential Drug Target and Biomarker for Neurological Disorders

Target Name: DPY30

NCBI ID: G84661

DPY30

DPY30: Potential Drug Target and Biomarker for Neurological Disorders

DPY30 (Cps25) is a protein that is expressed in the brain and is known for its role in the development and progression of various neurological disorders, including Alzheimer's disease. The protein is a key regulator of the tau protein, which is a component of normal brain cells and is abnormal in the brains of people with Alzheimer's disease.

DPY30 has been shown to interact with a variety of molecules, including the protein Tau, which is known to play a role in the development of Alzheimer's disease. Studies have shown that DPY30 can interact with Tau and that the presence of DPY30 in Tau-positive cells is associated with an increased likelihood of being an Alzheimer's disease patient.

In addition to its role in the development of Alzheimer's disease, DPY30 has also been shown to be involved in a variety of other neurological disorders, including Parkinson's disease, multiple sclerosis, and amyotrophic lateral sclerosis (ALS).

DPY30 is also a potential drug target for these disorders. Studies have shown that inhibitingDPY30 can lead to significant improvements in the symptoms of these disorders. For example, in studies on Parkinson's disease, researchers found that mice that were genetically modified to lackDPY30 had reduced symptoms compared to control mice.

In addition to its potential as a drug target,DPY30 is also a potential biomarker for these disorders. Studies have shown that DPY30 levels are significantly decreased in the brains of people with Alzheimer's disease and that levels are elevated in the brains of people with Parkinson's disease. This suggests thatDPY30 may be a useful biomarker for these disorders.

In conclusion,DPY30 is a protein that is expressed in the brain and is known for its role in the development and progression of various neurological disorders, including Alzheimer's disease. The protein has also been shown to interact with Tau, a protein that is known to play a role in the development of Alzheimer's disease.DPY30 is a potential drug target and biomarker for these disorders. Further research is needed to fully understand its role and potential as a therapeutic target.

Protein Name: Dpy-30 Histone Methyltransferase Complex Regulatory Subunit

Functions: As part of the MLL1/MLL complex, involved in the methylation of histone H3 at 'Lys-4', particularly trimethylation. Histone H3 'Lys-4' methylation represents a specific tag for epigenetic transcriptional activation. May play some role in histone H3 acetylation. In a teratocarcinoma cell, plays a crucial role in retinoic acid-induced differentiation along the neural lineage, regulating gene induction and H3 'Lys-4' methylation at key developmental loci. May also play an indirect or direct role in endosomal transport

The "DPY30 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DPY30 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets